ECO ANIMAL HEALTH GROUP PLC Logo

ECO ANIMAL HEALTH GROUP PLC

Develops pharmaceuticals for respiratory & enteric diseases in global swine and poultry markets.

EAH | IL

Overview

Corporate Details

ISIN(s):
GB0005056469 (+2 more)
LEI:
2138009XN9DJ3YP7OB55
Country:
United Kingdom
Address:
THE GRANGE, 100 HIGH STREET, N14 6BN LONDON
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

ECO Animal Health Group PLC is a global animal health biotechnology company specializing in the research, development, registration, and marketing of pharmaceutical and biological products. The company focuses on providing innovative solutions for economically important respiratory and enteric diseases, primarily targeting the swine and poultry markets. Its flagship product is Aivlosin® (marketed as Valosin® in some regions), a therapeutic used to improve animal health and performance, contributing to the global food supply chain. Committed to pioneering R&D, ECO Animal Health continually works on developing new products and enhancing its existing brands. The company operates through a global network of partnerships and distributors, maintaining a presence in over 70 countries.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-01 08:00
Board/Management Information
Head of Global R&D
English 12.1 KB
2025-08-21 13:29
Post-Annual General Meeting Information
Result of General Meeting
English 12.4 KB
2025-08-13 08:00
Share Issue/Capital Change
Block Listing Return
English 17.8 KB
2025-08-06 18:09
Major Shareholding Notification
Holding(s) in Company
English 25.3 KB
2025-07-17 08:00
Major Shareholding Notification
Holding(s) in Company
English 40.5 KB
2025-07-15 14:00
Director's Dealing
Director/PDMR Shareholding
English 22.8 KB
2025-07-14 08:00
Earnings Release
Results for the year ended 31 March 2025
English 1.2 MB
2025-07-08 17:10
Pre-Annual General Meeting Information
Notice of General Meeting and Notice of Results
English 15.3 KB
2025-03-13 08:00
Regulatory News Service
R&D Day
English 11.7 KB
2025-03-03 08:00
Regulatory News Service
Submission of Marketing Authorisation Application
English 13.9 KB
2025-02-24 17:08
Major Shareholding Notification
Holding(s) in Company
English 21.9 KB
2025-02-19 08:00
M&A Activity
Disposal of non-core assets
English 11.4 KB
2025-02-18 08:00
Remuneration Information
Block listing Interim Review
English 14.9 KB
2025-02-13 08:00
Report Publication Announcement
Notice of R&D Day
English 10.2 KB
2024-12-20 08:00
Major Shareholding Notification
Holding(s) in Company
English 21.9 KB

Automate Your Workflow. Get a real-time feed of all ECO ANIMAL HEALTH GROUP PLC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for ECO ANIMAL HEALTH GROUP PLC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Formycon AG Logo
Develops cost-effective biosimilars for ophthalmology, immunology, and other chronic diseases.
Germany FYB
Friulchem Logo
CDMO for animal health, providing vet pharma & supplement solutions for pets and livestock.
Italy FCM
Fuji Pharma Co.,Ltd. Logo
Specializes in hormone medicines for ob/gyn, injectables, and contract manufacturing.
Japan 4554
Fuso Pharmaceutical Industries,Ltd. Logo
Manufactures essential pharmaceuticals like dialysis drugs, infusions, and injections for healthcare.
Japan 4538
FutureChem Co., Ltd. Logo
Develops radiopharmaceuticals & diagnostic agents for cancer, Alzheimer's, and Parkinson's disease.
South Korea 220100
Future Medicine  Co., Ltd. Logo
Clinical-stage biopharma developing novel synthetic drugs for inflammation, fibrosis, and oncology.
South Korea 341170
Develops long-acting injectable therapies for chronic diseases and cancer.
South Korea 456160
Gabather AB Logo
Developing novel GABAA receptor drugs for neuropsychiatric disorders.
Sweden GABA
Galapagos NV Logo
Biotech firm developing novel CAR-T cell therapies for oncology via a rapid delivery platform.
Belgium GLPG
Galderma Group AG Logo
A pure-play dermatology company with aesthetics, skincare, and therapeutic solutions.
Switzerland GALD

Talk to a Data Expert

Have a question? We'll get back to you promptly.